2160
vs
H
Hang Seng (Hong Kong)
2160
Over the past 12 months, Microport Cardioflow Medtech Corp has significantly outperformed Hang Seng (Hong Kong), delivering a return of +186% compared to the Hang Seng (Hong Kong)'s +8% growth.
Stocks Performance
2160 vs Hang Seng (Hong Kong)
Performance Gap
2160 vs Hang Seng (Hong Kong)
Performance By Year
2160 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Microport Cardioflow Medtech Corp
Glance View
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.
